Arcutis biotherapeutics stock.

Find the latest Arcutis Biotherapeutics, Inc. (ARQT) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Which technical analysis tools can be used to analyze Arcutis Biotherapeutics, Inc.? Check out various oscillators, moving averages and other technical ...Nov 29, 2023 · Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis harnesses our unique ... August 8, 2023 at 4:02 PM · 11 min read. Arcutis Biotherapeutics, Inc. Achieved total revenues of $5.2 million in the second quarter of 2023. Net product revenues for ZORYVE® (roflumilast) cream ...

As such, now is a great time to consider investing in Arcutis Biotherapeutics. Share Price. Arcutis Biotherapeutics had a rough first trading day on Monday. Its stock opened at $14.0 and closed at $13.3, a decrease of 3.8% from its previous closing price of $13.8. Despite this, investors should still consider investing in …Arcutis is building momentum around its Zoryve segment with a string of recent advancements at the back end of FY22 and into the new year. Find out why ARQT stock is a Buy.

Currently, Arcutis Biotherapeutics has an average volume of 1.03M. Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock.

About Arcutis Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient …--Arcutis Biotherapeutics, Inc., ... today reported the grant of an aggregate of 90,500 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 106,500 ...Earnings for Arcutis Biotherapeutics are expected to grow in the coming year, from ($3.78) to ($2.65) per share. Arcutis Biotherapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 27th, 2024 based off prior year's report dates.Shares of Arcutis Biotherapeutics ( ARQT -3.16%) climbed 21.2% for the week after rising as high as 23.8%, according to data provided by S&P Global Market Intelligence. The medical dermatology ...Arcutis Biotherapeutics (ARQT) Stock Price, News & Info | The Motley Fool Arcutis Biotherapeutics (NASDAQ: ARQT) $2.20 (-6.4%) -$0.15 Price as of November 8, 2023, 4:00 p.m. ET Overview...

NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shown.

As of May 30, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $7.81. Arcutis Biotherapeutics Inc is down 7.02% from its previous closing price of $8.40. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $8.11 and $8.57. Currently, there are 61.17 million shares of Arcutis Biotherapeutics Inc ...

WESTLAKE VILLAGE - Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration (FDA) has accepted its supplemental new drug application (sNDA) for …In addition, Arcutis has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock at the public offering price, less …WESTLAKE VILLAGE, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical …Stock Price Forecast. According to 8 stock analysts, the average 12-month stock price forecast for ARQT stock stock is $33.38, which predicts an increase of 1,268.03%. The lowest target is $4.00 and the highest is $50. On average, analysts rate ARQT stock stock as a strong buy.7. Arcutis Biotherapeutics. @ArcutisBio. ·. May 15. Fact: #atopicdermatitis (AD) is the most common type of eczema, affecting approximately 9.6 million children in the U.S. alone. A recent study uncovered how the burden of AD is perceived by children, adolescents, their caregivers, and dermatologists. Learn more below.Volume, 2.35M. Market Value, $179.33M. Shares Outstanding, 94.38M. EPS (TTM), -$4.9489. P/E Ratio (TTM), N/A. Dividend Yield, N/A. Latest Dividend, N/A.

ARCUTIS BIOTHERAPEUTICS INC Item 1(b) Address of issuer's principal executive offices: ----- 3027 TOWNSGATE ROAD, SUITE 300 WESTLAKE VILLAGE CA 91361 Item 2. 2(a) Name of person filing: ... Common Stock 2(e) CUSIP No.: See Cover Page Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c),Arcutis Biotherapeutics (NASDAQ:ARQT) has observed the following analyst ratings within the last quarter: These 6 analysts have an average price target of $34.83 versus the current price of ...The Arcutis Biotherapeutics Inc stock price fell by -6.86% on the last day (Wednesday, 29th Nov 2023) from $2.04 to $1.90.During the last trading day the stock fluctuated 20.00% from a day low at $1.88 to a day high of $2.25.The price has fallen in 6 of the last 10 days and is down by -12.84% for this period. Volume has increased on the …Nov 8, 2022 · The replay of the webcast will be available on the Arcutis website following the call. About Arcutis . Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions. Since the trade, Arcutis Biotherapeutics Inc's stock has declined by 20.89%, and it has plummeted by 91.54% since its IPO. The year-to-date performance is also down by 86.8%. With no applicable GF ...A Different Perspective. Arcutis Biotherapeutics shareholders may not have made money over the last year, but their total loss of 5.5% isn't as bad as the market loss of around 5.5%.

May 10, 2023 1:55 PM ET Arcutis Biotherapeutics, Inc. (ARQT) By: Jonathan Block, SA News Editor. CharlieAJA. Arcutis Biotherapeutics ( NASDAQ: ARQT) is down ~20% in Wednesday afternoon trading ...Another classic case of short-interest stocks, Arcutis Biotherapeutics (NASDAQ:ARQT) on paper seems incredibly relevant. Leveraging advanced innovations in the field of dermatology, ...

Complete Arcutis Biotherapeutics Inc. stock information by Barron's. View real-time ARQT stock price and news, along with industry-best analysis. WESTLAKE VILLAGE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the quarter ended March 31, 2022, and provided a business update. ...Health Technology. Industry. Pharmaceuticals: Major. No executives to display. Corporate headquarters. --, --. Find real-time ARQT - Arcutis Biotherapeutics Inc stock quotes, company profile, news ...Get the latest Arcutis Biotherapeutics, Inc. (ARQT) stock news and headlines to help you in your trading and investing decisions. ... Nov. 29, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc ...Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Alkermes, and Relmada Therapeutics. According to TipRanks , Ear has an average return of -1.6% and a 23.68% ...WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced the commencement of an underwritten public offering of $100.0 million of shares of its common stock and ...

ARQT is the ticker symbol for Arcutis Biotherapeutics, Inc., a company that develops immuno-dermatology products. The stock price, news, quote and history of ARQT are shown on Yahoo Finance. See the latest performance outlook, earnings date, dividend yield, research reports and more.

The stock options have a ten-year term and an exercise price of $7.65 per share, equal to the per share closing price of Arcutis’ common stock as reported by Nasdaq on June 1, 2023. Arcutis is ...

9 analysts have issued twelve-month target prices for Arcutis Biotherapeutics' shares. Their ARQT share price targets range from $6.00 to $57.00. On average, they anticipate the company's stock price to reach $29.67 in the next year. This suggests a possible upside of 1,390.8% from the stock's current price.Real time Arcutis Biotherapeutics (ARQT) stock price quote, stock graph, news & analysis. Oct 20, 2023 · Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with ... WESTLAKE VILLAGE, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, …Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated ...What does smart money think about Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)? At Q1's end, a total of 8 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of 8 from ...Arcutis Biotherapeutics' CEO is Frank Watanabe, appointed in Jan 2016, has a tenure of 7.83 years. total yearly compensation is $4.58M, comprised of 12.9% salary and 87.1% bonuses, including company stock and options. directly owns 0.45% of the company’s shares, worth $798.75K. The average tenure of the management team and the board of ...Arcutis Biotherapeutics Inc. Watch list Set a price target alert Open Last Updated: Dec 1, 2023 1:02 p.m. EST Real time quote $ 1.9450 0.1050 5.71% Previous Close $1.8400 …About Arcutis Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis …

As of April 11, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $12.89. Arcutis Biotherapeutics Inc is up 4.2% from its previous closing price of $12.37. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $11.83 and $12.47. Currently, there are 61.04 million shares of Arcutis Biotherapeutics ...WESTLAKE VILLAGE - Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) to expand the indication of ZORYVE (roflumilast) cream 0.3% for the topical treatment of ...66.61%. Get the latest Arcutis Biotherapeutics Inc (ARQT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment ... Oct. 9, 2023, 08:27 AM Sean Kim PhD, an analyst from JonesTrading, reiterated the Buy rating on Arcutis Biotherapeutics ( ARQT – Research Report ). The associated price target is $44.00. Sean...Instagram:https://instagram. best book on options trading for beginnersnextera energy stock dividendutvtxcheap jewellery insurance Get Arcutis Biotherapeutics Inc (ARQT.OQ) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments. jsvaxjohnson and johnson spin off WESTLAKE VILLAGE, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration (FDA) has accepted for review the company’s new drug application (NDA) for ... dow index list Oct 20, 2023 · WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of common stock and, in lieu of common ... Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with ...Nov 29, 2023 · The Arcutis Biotherapeutics Inc stock price fell by -0.529% on the last day (Wednesday, 22nd Nov 2023) from $1.89 to $1.88. During the last trading day the stock fluctuated 17.51% from a day low at $1.77 to a day high of $2.08. The price has fallen in 6 of the last 10 days and is down by -14.55% for this period.